The Sick Adipose Tissue: New Insights Into Defective Signaling and Crosstalk With the Myocardium.

Adipose tissue (AT) biology is linked to cardiovascular health since obesity is associated with cardiovascular disease (CVD) and positively correlated with excessive visceral fat accumulation. AT signaling to myocardial cells through soluble factors known as adipokines, cardiokines, branched-chain amino acids and small molecules like microRNAs, undoubtedly influence myocardial cells and AT function via the endocrine-paracrine mechanisms of action. Unfortunately, abnormal total and visceral adiposity can alter this harmonious signaling network, resulting in tissue hypoxia and monocyte/macrophage adipose infiltration occurring alongside expanded intra-abdominal and epicardial fat depots seen in the human obese phenotype. These processes promote an abnormal adipocyte proteomic reprogramming, whereby these cells become a source of abnormal signals, affecting vascular and myocardial tissues, leading to meta-inflammation, atrial fibrillation, coronary artery disease, heart hypertrophy, heart failure and myocardial infarction. This review first discusses the pathophysiology and consequences of adipose tissue expansion, particularly their association with meta-inflammation and microbiota dysbiosis. We also explore the precise mechanisms involved in metabolic reprogramming in AT that represent plausible causative factors for CVD. Finally, we clarify how lifestyle changes could promote improvement in myocardiocyte function in the context of changes in AT proteomics and a better gut microbiome profile to develop effective, non-pharmacologic approaches to CVD.

The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror.

Type 2 Diabetes Mellitus (T2DM) is one of the most prevalent chronic metabolic disorders, and insulin has been placed at the epicentre of its pathophysiological basis. However, the involvement of impaired alpha (α) cell function has been recognized as playing an essential role in several diseases, since hyperglucagonemia has been evidenced in both Type 1 and T2DM. This phenomenon has been attributed to intra-islet defects, like modifications in pancreatic α cell mass or dysfunction in glucagon's secretion. Emerging evidence has shown that chronic hyperglycaemia provokes changes in the Langerhans' islets cytoarchitecture, including α cell hyperplasia, pancreatic beta (ß) cell dedifferentiation into glucagon-positive producing cells, and loss of paracrine and endocrine regulation due to ß cell mass loss. Other abnormalities like α cell insulin resistance, sensor machinery dysfunction, or paradoxical ATP-sensitive potassium channels (KATP) opening have also been linked to glucagon hypersecretion. Recent clinical trials in phases 1 or 2 have shown new molecules with glucagon-antagonist properties with considerable effectiveness and acceptable safety profiles. Glucagon-like peptide-1 (GLP-1) agonists and Dipeptidyl Peptidase-4 inhibitors (DPP-4 inhibitors) have been shown to decrease glucagon secretion in T2DM, and their possible therapeutic role in T1DM means they are attractive as an insulin-adjuvant therapy.

[Malondialdehyde and reduced glutathione increase in patients with chronic stable ischaemic cardiopathy]. / Incremento de las concentraciones séricas de malondialdehído y glutatión reducido en pacientes con cardiopatía isquémica crónica estable.

BACKGROUND AND OBJECTIVE: Cardiovascular diseases are associated with the ischemia/reperfusion phenomena and therefore to the oxidation/antioxidation balance. The aim of this study was to determine malondialdehyde, nitric oxide, glutathione, ascorbic and dehydroascorbic acid in patients with chronic ischemic heart disease. PATIENTS AND METHOD: 32 male patients, with chronic ischemic heart disease, between 40 and 60 years of age were studied. These individuals were divided in two groups: 16 with hypertension and 16 without hypertension. Both groups were compared with 31 healthy male subjects (control group). RESULTS: Significant differences (p < 0.001) was observed in malondialdehyde between no-hypertension ischemic group: 5.3 (1.5) microM and the hypertension ischemic group: 4.8 (1.3) microM in contrast with the healthy group: 2.2 (0.5) microM. Hypertension ischemic group showed significant greater reduced glutation levels: 286.1 (31.4) microg/ml than control group 262.0 (38.8) microg/ml; p < 0.03 and no-hypertension ischemic group: 256.4 (41.5) microg/ml; p < 0.02. No significant difference in the rest of the parameters for all study groups. CONCLUSIONS: Oxidation/antioxidation balance during chronic ischemic heart disease can be considered as a good metabolic ischemia indicator, that used in the monitoring and therapeutic evaluation could detect molecular changes that anticipate installation of tissue damage.

Incremento de las concentraciones séricas de malondialdehído y glutatión reducido en pacientes con cardiopatía isquémica crónica estable / Malondialdehide and reduced glutathione increase in patients with chronic stable ischaemic cardiopathy

FUNDAMENTO Y OBJETIVO: Las enfermedades cardiovasculares están asociadas a isquemia/reperfusión. El objetivo de este estudio fue determinar el malondial de hído,óxido nítrico, glutatión reducido, ácido ascórbico y ácido deshidroascórbico en cardiópatas isquémicos crónicos. PACIENTES Y MÉTODO: Se estudió a 32 varones con cardiopatía isquémica crónica, de entre 40 y 60años, que se dividieron en 2 grupos: uno constituido por 16 sujetos hipertensos y el segundo formado por 16 pacientes sin hipertensión. Ambos grupos se compararon con 31 varones sanos (grupo control).RESULTADOS: El malondial de hído presentó un incremento estadísticamente significativo (p < 0,001) en los pacientes con cardiopatía no hipertensiva (media[desviación estándar] de 5,3 [1,5] µM) y en los que tenían cardiopatía hipertensiva (4,8 [1,3] µM) comparados con los individuos sanos (2,2 [0,5] µM). El grupo de cardiópatas hipertensos presentó un valor de glutatión reducido significativamente mayor(286,1 [31,4] µg/ml) que el de los individuos cardiópatas sin hipertensión: (256,4 [41,5] µg/ml) (p <0,02) y que el grupo control (262,0 [38,8] µg/ml)(p < 0,03). No hubo diferencias significativas en el resto de los parámetros para todos los grupos. CONCLUSIONES: El equilibrio oxidación/antioxidación durante la cardiopatía isquémica crónica puede considerarse como un buen indicador metabólico de isquemia/reperfusión y llegar a detectar los cambios moleculares que anteceden a la instauración de la lesión tisular

BACKGROUND AND OBJECTIVE: Cardiovascular diseasesare associated with the ischemia/reperfusion phenomenaand there fore to the oxidation/antioxidation balance. The aim of this study was to determine malondialhehyde, nitric oxide, glutathione, ascorbic and dehydroascorbic acid in patients with chronic ischemic heart disease. PATIENTS AND METHOD: 32 male patients, with chronicischemic heart disease, between 40 and 60 years of age were studied. These individuals were divided in two groups: 16 with hypertension and 16without hypertension. Both groups were compared with 31 healthy male subjects (control group).RESULTS: Significant differences (p < 0.001) was observed in malondialdehyde between no-hypertension ischemic group: 5.3 (1.5) µM and the hypertension ischemic group: 4.8 (1.3) µM in contrast with the healthy group: 2.2 (0.5) µM. Hypertension ischemic group showed significant greater reduced glutation levels: 286.1 (31.4)µg/ml than control group 262.0 (38.8) µg/ml; p <0.03 and no-hypertension ischemic group: 256.4(41.5) µg/ml; p < 0.02. No significant difference in the rest of the parameters for all study groups. CONCLUSIONS: Oxidation/antioxidation balance during chronic ischemic heart disease can be considered as a good metabolic ischemia indicator, that used in the monitoring and therapeutic evaluation could detect molecular changes that anticipatein stallation of tissue damage